Bifogade filer
AroCell Interim Report Q3 2023
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
A word from the CEO
”The first nine months have been highly favorable for AroCell, with almost a 40% increase in sales compared to previous years. During the third quarter, AroCell continues to experience a growing order intake in both bacteriology and oncology. To address the growing demand, we are consistently increasing our production capacity, both through internal expansion and in collaboration with our partners. As a result of increased demand and a temporary extension of delivery times with suppliers, we are experiencing a shift in revenue recognition from the third quarter to future periods. Simultaneously, the work to automate several of our biomarkers is progressing as planned. I am pleased to report that we are in a good position to take the company further in its growth.”
Anders Hultman, CEO
Reporting period July 1st – September 30th
- Net sales amounted to KSEK 10,700 (10,401).
- Profit after financial items amounted to KSEK -13,003 (-11,069)*.
- Cash flow from operating activities for the period amounted to KSEK -5,661 (-1,856).
- Earnings per share before and after dilution amounted to SEK -0.06 (-0.05).
- Cash and cash equivalents at the end of the period amounted to KSEK 51,512 (67,825).
* Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.
Reporting period January 1st – September 30th
- Net sales amounted to KSEK 33,528 (24,519).
- Profit after financial items amounted to KSEK -42,161 (-42,779)*.
- Cash flow from operating activities for the period amounted to KSEK -12,525 (-11,373).
- Earnings per share before and after dilution amounted to SEK -0.18 (-0.20).
- Cash and cash equivalents at the end of the period amounted to KSEK 51,512 (67,825).
* Includes costs for goodwill amortization of KSEK 29,684 (29,684) for the period.
Events during the period July 1st – September 30th
- AroCell has signed an additional agreement with ZECEN Biotech for the development of its third tumor marker product, TK 210 ELISA, on ZECEN Biotech’s automated platforms. This collaboration is an important milestone for AroCell as the company strives to expand its product range and improve cancer diagnostics.
- A recent study has been published, providing additional evidence for the use of UBC® Rapid as a diagnostic and monitoring tool for bladder cancer. This study stands as the first of its kind, comparing various commercial rapid tests among a large group of patients with bladder cancer and healthy individuals at a single center.
- New study focused on the clinical applications of the TK 210 ELISA for ovarian cancer has been accepted for publication in the Karger Oncology journal. This study highlights the clinical utility of TK1-specific activity (TK1 SA) in the early detection of ovarian cancer.
Events after the period
- After the conclusion of the period, the warrant program, as decided by the annual general meeting, has been implemented. The total number of warrants issued is 5,000,000, with a premium of 0.05 öre. The program has a duration of 3 years and is allocated among various groups, including the CEO, management team, other executives, and other employees. The strike price has been set at SEK 1, and the warrants are subscribed on market terms.
Interim report January 1st – September 30th, 2023 (Link)